title: Evaluation of the use of captopril on peritoneal fibrosis induced in rats by the use of glucose solution 4.25%.
abstract: BACKGROUND
  Chronic renal failure has alarming incidence all over the world in this century. Among the modalities of dialytic treatment, peritoneal dialysis has a major spot. This method of dialytic treatment may present complications, and among those is peritoneal fibrosis. It occurs in patients submitted to peritoneal dialysis along years. It's most dangerous form is sclerosing encapsulant peritonitis, wich leads to a need of change in modality and many times lead to death.
  
  
  OBJECTIVE
  Study the influence of using captopril on the peritoneal fibrosis induced in rats using solution with glucoses 4.25%.
  
  
  METHODS
  Prospective controlled study in 20 non-uremic Wistar rats. The animals received a peritoneal infusion of 10 ml/100g of peritoneal dialysis solution glucose 4.25% on a daily basis. The animals were divided in two groups: experimental and control. The experimental group received captopril 30 mg/kg/d, by a gastric tube. The control group did not receive any drug. The follow-up was 21 and 49 days. At the end, one surgical procedure was performed to get histological samples of visceral and parietal peritoneum. The samples were analyzed using Hematoxylin Eosin and Sirius Red, to evaluate the severity of the fibrosis.
  
  
  RESULTS
  The analysis showed that the intensity of the fibrosis, the peritoneal thickness and the cell number in experimental and control groups were not statistically significant different in experimental and control groups.
  
  
  CONCLUSIONS
  Our findings indicate that captopril do not decrease the intensity of fibrosis on the peritoneal membrane that happens on rats on peritoneal dialysis.
authors.forename: Adriana Fátima Menegat
authors.initials: AF
authors.lastname: Schuinski
authors.forename: Gilberto
authors.initials: G
authors.lastname: Baroni
authors.forename: Roberto Flávio
authors.initials: RF
authors.lastname: Pecoits Filho
authors.forename: Fernando
authors.initials: F
authors.lastname: Meyer
authors.forename: Marina Lindstrom Wittica
authors.initials: ML
authors.lastname: Cerqueira
authors.forename: Maria Angélica Alexandre
authors.initials: MA
authors.lastname: da Silva
authors.forename: Viviane
authors.initials: V
authors.lastname: de Carvalho
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002216:Captopril / Q000627:therapeutic use*; D005947:Glucose / Q000008:administration & dosage*; D008297:Male; D010530:Peritoneal Dialysis; D056627:Peritoneal Fibrosis / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D005947:Glucose